Call for entries to Rainer Rudolph Foundation prizes
Closing date is 31 March
Friends, companions, former colleagues and staff of the late Professor Dr Rainer Rudolph established The Rainer Rudolph Foundation in 2011 to honour his scientific work. Prior to his death in 2009, Professor Rudolph was among the world’s leading protein biochemists as well as the co-founder of Scil Proteins, the company which now sponsors The Rainer Rudolph Foundation.
Dr Ulrike Fiedler, chief executive of the Foundation and Scil Proteins, said: ‘During his work, Professor Rudolph placed particular emphasis on linking scientific research with industrial applications and consequently, the foundation of Scil Proteins was a logical step for him. Through the years, we came to know and appreciate Professor Rudolph as a highly respected scientist and competent industrial partner. The Rainer Rudolph prizes have been established to encourage upcoming generations of scientists to excel in their work and therefore, I hope many young researchers in the fields of protein biochemistry and biotechnology will apply.’
You may also like
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical
Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026
Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment